Evidence map›Paper›PMID 23307060›Full record

ReviewModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2013

Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Shuji Ogino, Paul Lochhead, Andrew T Chan, Reiko Nishihara, Eunyoung Cho, Brian M Wolpin, Jeffrey A Meyerhardt, Alexander Meissner, Eva S Schernhammer, Charles S Fuchs and 1 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Higher Levels ofMedical sciences (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Review
  9. Microbial manipulators:Journal of oral microbiology · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Field cancerization in breast cancer.The Journal of pathology · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Shuji OginoDepartment of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02215, USA. shuji_ogino@dfci.harvard.edu
Paul Lochhead
Andrew T Chan
Reiko Nishihara
Eunyoung Cho
Brian M Wolpin
Jeffrey A Meyerhardt
Alexander Meissner
Eva S Schernhammer
Charles S Fuchs
Edward Giovannucci
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USBroad Institute · USUniversity of Aberdeen · GB

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & PathogenesisR01CA124908 · NCI · DANA-FARBER CANCER INST · PI FUCHS, CHARLES S · 2007 to 2012
$4.3M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
The Influence of Diet and Lifestyle on Patients with Advanced Colorectal CancerR01CA149222 · NCI · DANA-FARBER CANCER INST · PI MEYERHARDT, JEFFREY A · 2010 to 2014
$2.4M
Dietary Methyl Score, Genomic DNA Methylation and Colorectal CancerR01CA136950 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHO, EUNYOUNG · 2009 to 2012
$1.3M
Chief Scientist Office CAF/10/15NCI NIH HHS 1UM1 CA167552NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA124908NCI NIH HHS R01 CA136950NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA149222NCI NIH HHS R01 CA151993NCI NIH HHS UM1 CA167552NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

Epigenetics acts as an interface between environmental/exogenous factors, cellular responses, and pathological processes. Aberrant epigenetic signatures are a hallmark of complex multifactorial diseases (including neoplasms and malignancies such as leukemias, lymphomas, sarcomas, and breast, lung, prostate, liver, and colorectal cancers). Epigenetic signatures (DNA methylation, mRNA and microRNA expression, etc) may serve as biomarkers for risk stratification, early detection, and disease classification, as well as targets for therapy and chemoprevention. In particular, DNA methylation assays are widely applied to formalin-fixed, paraffin-embedded archival tissue specimens as clinical pathology tests. To better understand the interplay between etiological factors, cellular molecular characteristics, and disease evolution, the field of 'molecular pathological epidemiology (MPE)' has emerged as an interdisciplinary integration of 'molecular pathology' and 'epidemiology'. In contrast to traditional epidemiological research including genome-wide association studies (GWAS), MPE is founded on the unique disease principle, that is, each disease process results from unique profiles of exposomes, epigenomes, transcriptomes, proteomes, metabolomes, microbiomes, and interactomes in relation to the macroenvironment and tissue microenvironment. MPE may represent a logical evolution of GWAS, termed 'GWAS-MPE approach'. Although epigenome-wide association study attracts increasing attention, currently, it has a fundamental problem in that each cell within one individual has a unique, time-varying epigenome. Having a similar conceptual framework to systems biology, the holistic MPE approach enables us to link potential etiological factors to specific molecular pathology, and gain novel pathogenic insights on causality. The widespread application of epigenome (eg, methylome) analyses will enhance our understanding of disease heterogeneity, epigenotypes (CpG island methylator phenotype, LINE-1 (long interspersed nucleotide element-1; also called long interspersed nuclear element-1; long interspersed element-1; L1) hypomethylation, etc), and host-disease interactions. In this article, we illustrate increasing contribution of modern pathology to broader public health sciences, which attests pivotal roles of pathologists in the new integrated MPE science towards our ultimate goal of personalized medicine and prevention.

Indexed as

EpidemiologyEpigenomicsHumansPathology, MolecularPrecision Medicine

Identifiers

PMID23307060
PMCPMC3637979
OpenAlexW2071441216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.